Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II.
Inhibitors of PPII (pyroglutamyl-peptidase II) (EC 3.4.19.6) have potential applications as investigative and therapeutic agents. The rational design of inhibitors is hindered, however, by the lack of an experimental structure for PPII. Previous studies have demonstrated that replacement of histidine in TRH (thyrotropin-releasing hormone) with asparagine produces a competitive PPII inhibitor (Ki 17.5 microM). To gain further insight into which functional groups are significant for inhibitory activity, we investigated the effects on inhibition of structural modifications to Glp-Asn-ProNH2 (pyroglutamyl-asparaginyl-prolineamide). Synthesis and kinetic analysis of a diverse series of carboxamide and C-terminally extended Glp-Asn-ProNH2 analogues were undertaken. Extensive quantitative structure-activity relationships were generated, which indicated that key functionalities in the basic molecular structure of the inhibitors combine in a unique way to cause PPII inhibition. Data from kinetic and molecular modelling studies suggest that hydrogen bonding between the asparagine side chain and PPII may provide a basis for the inhibitory properties of the asparagine-containing peptides. Prolineamide appeared to be important for interaction with the S2' subsite, but some modifications were tolerated. Extension of Glp-Asn-ProNH2 with hydrophobic amino acids at the C-terminus led to a novel set of PPII inhibitors active in vitro at nanomolar concentrations. Such inhibitors were shown to enhance recovery of TRH released from rat brain slices. Glp-Asn-Pro-Tyr-Trp-Trp-7-amido-4-methylcoumarin displayed a Ki of 1 nM, making it the most potent competitive PPII inhibitor described to date. PPII inhibitors with this level of potency should find application in exploring the biological functions of TRH and PPII, and potentially provide a basis for development of novel therapeutics.
Kelly
Julie A
JA
Department of Biochemistry, Trinity College Dublin, Dublin 2, Ireland. kellyja@tcd.ie
Scalabrino
Gaia A
GA
Slator
Gillian R
GR
Cullen
Aoife A
AA
Gilmer
John F
JF
Lloyd
David G
DG
Bennett
Geoffrey W
GW
Bauer
Karl
K
Tipton
Keith F
KF
Williams
Carvell H
CH
D000595:Amino Acid Sequence; D000818:Animals; D001216:Asparagine / Q000737:chemistry / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D006868:Hydrolysis / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011392:Proline / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding; D011751:Pyroglutamyl-Peptidase I / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013329:Structure-Activity Relationship; D013973:Thyrotropin-Releasing Hormone / Q000737:chemistry / Q000378:metabolism
D004791:Enzyme Inhibitors; D009842:Oligopeptides; D013973:Thyrotropin-Releasing Hormone; D001216:Asparagine; D011392:Proline; D011751:Pyroglutamyl-Peptidase I